The Pyruvate Kinase PKLR pipeline drugs market research report outlays comprehensive information on the Pyruvate Kinase PKLR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Pyruvate Kinase PKLR pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Hematological Disorders, and Genetic Disorders which include the indications Anemia, Sickle Cell Disease, and Genetic Disorders. It also reviews key players involved in Pyruvate Kinase PKLR targeted therapeutics development with respective active and dormant or discontinued products.
The Pyruvate Kinase PKLR pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 2, 1, 1, and 1 respectively.
Pyruvate Kinase PKLR overview
Pyruvate kinase (PK) is an enzyme that plays a crucial role in glycolysis, a central metabolic pathway responsible for the conversion of glucose into pyruvate. There are different isoforms of pyruvate kinase, and one of them is pyruvate kinase PKLR, which is encoded by the PKLR gene. The PKLR gene provides instructions for making the pyruvate kinase PKLR enzyme. This isoform is primarily found in the liver (L) and red blood cells (R). Mutations in the PKLR gene can lead to hereditary pyruvate kinase deficiency, a rare genetic disorder characterized by a reduced activity of pyruvate kinase. This deficiency affects the normal function of red blood cells, leading to hemolytic anemia.
For a complete picture of Pyruvate Kinase PKLR’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
